Will Aardvark Therapeutics stock go up?

According to Danelfin AI, Aardvark Therapeutics has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (53.39%) is +2.57% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Aardvark Therapeutics stock?

The Aardvark Therapeutics target price is $13.83 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Aardvark Therapeutics stock right now?

Aardvark Therapeutics has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (53.39%) is +2.57% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Aardvark Therapeutics stock is a good buy .

Is Aardvark Therapeutics undervalued right now?

Based on analysts, the average price target upside for Aardvark Therapeutics is +145.30% (1Y). According to Danelfin AI, Aardvark Therapeutics has today an AI Score of 5/10 (Hold Rating).

What was the price range of Aardvark Therapeutics stock over the past 12 months?

The Aardvark Therapeutics stock price range over the past 12 months has been $3.48 - $17.41.

What is going on with Aardvark Therapeutics stock in the last 3 months?

The Aardvark Therapeutics stock performance in the last quarter has been +49.60%.

Does Aardvark Therapeutics offer dividend payments?

No, Aardvark Therapeutics does not currently pay dividends.

What is the current market capitalization of Aardvark Therapeutics?

Aardvark Therapeutics's market cap is $122.61M, as of 2026-07-02 08:00.

When is the next AARD earnings report date?

AARD will publish its next earnings report on 2026-05-07.

Aardvark Therapeutics Inc (AARD) AI Stock Analysis

Advanced Chart

Custom range

Jul 2, 2025

→

Jul 2, 2026

Custom range

Jul 2, 2025

→

Jul 2, 2026

AARD AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Aardvark Therapeutics Inc today receives an AI Score of 5/10, which translates to a Hold rating. The stock has a 53% probability of outperforming the market in the next 3 months, which is 2% higher than the average probability of any stock (51%). The top positive contributors include Operating Cash Flow (Qtr Discrete) (impact +2.37%), Fundamentals Impact (Long Tail) (+1.70%), and Performance (YTD) (+0.61%), despite the latter being in the bottom 10%. On the detractor side, Maximum Volatility (top 10%, impact -0.87%), Alpha YTD (bottom 10%, -0.64%), and Chart Pattern (180d) (-0.58%) weigh down the probability. Notable data points include Operating Cash Flow in the bottom 20% with a value of -18.87, yet it positively influences the model. Maximum Volatility is in the top 10% at 13.23%, indicating high risk. Alpha YTD is in the bottom 10% at -66.4%, reflecting poor risk-adjusted returns. The Earnings Countdown of -50 days (bottom 30%) suggests the last earnings report was about 50 days ago. Overall, the stock’s probability is slightly above average, supported by operational cash flow and fundamentals, but held back by high volatility and negative alpha, justifying the neutral Hold rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Earnings Quality+2.90%
Stability and reliability of reported earnings
Valuation+2.18%
How the stock is priced relative to its fundamentals
Size & Liquidity+0.31%
Company size and trading liquidity
Growth+0.26%
Expected pace of revenue and earnings expansion
Sentiment+0.15%
How analysts and the market view the stock

Momentum-1.83%
Direction and strength of recent price movements
Volatility-1.41%
How much the stock price tends to fluctuate

AARD probability advantage of beating the market (3M):

+2.57%

AI Score

Hold

Aardvark Therapeutics (AARD) has an AI Score of 5/10 (Hold) because, according to an overall analysis, it has a probability advantage of +2.57% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of AARD (53.39%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
AARD probability advantage of beating the market (3M)+2.57%
AARD probability of beating the market (3M)53.39%

AARD probability advantage of beating the market (3M): +2.57%

The AI-powered overall analysis of Aardvark Therapeutics (AARD) is based on the 25 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of AARD:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Operating Cash Flow (Qtr Discrete)	-18.87		+2.37%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+1.70%
Technical	Maximum Volatility	13.23%		-0.87%
Technical	Alpha YTD	-0.66%	N/A	-0.64%
Technical	Performance (YTD)	-0.57%	N/A	+0.61%
Technical	Chart Pattern (180d)	figure_9	N/A	-0.58%
Technical	Distance from KAMA (20d)	0.22%		-0.55%
Fundamental	Total Depreciation and Amortization - (Quarter)	-0.11	N/A	+0.53%
Technical	Alpha 6M	-0.67%	N/A	-0.53%
Fundamental	Tangible Shareholders' Equity	86.99		+0.48%
Technical	Upgrade to unlock			+0.46%
Technical	Upgrade to unlock			-0.45%
Sentiment	Upgrade to unlock			+0.45%
Sentiment	Upgrade to unlock			-0.42%
Sentiment	Upgrade to unlock			-0.42%

Rest of Alpha Signals: +0.45%

AARD probability advantage of beating the market (3M)Total:+2.57%
AARD AI Score

Significant changes Vs previous day

AARD Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$5.64
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

AARD Proven Hold Signal & Price Forecast

This is the price chart for AARD from January 1, 2026 until today. The chart indicates, in yellow, the 80 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

AARD Average Past Performance & Win Rate

Three months after its 179 Hold signals since July 2026, AARD had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

179 Past AARD Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				0.00%
Average Alpha				0.00%
Win Rate (% Positive Perf.)				0.00%
% Positive Alpha				0.00%

AARD Frequently Asked Questions

Will Aardvark Therapeutics stock go up?
According to Danelfin AI, Aardvark Therapeutics has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (53.39%) is +2.57% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Aardvark Therapeutics stock?
Is it a good time to buy, sell, or hold Aardvark Therapeutics stock right now?
Is Aardvark Therapeutics undervalued right now?
What was the price range of Aardvark Therapeutics stock over the past 12 months?
What is going on with Aardvark Therapeutics stock in the last 3 months?
Does Aardvark Therapeutics offer dividend payments?
What is the current market capitalization of Aardvark Therapeutics?
When is the next AARD earnings report date?

Aardvark Therapeutics Inc Company Profile

Aardvark Therapeutics Inc (AARD) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutic candidates. It focuses on creating innovative medicines designed to address significant unmet medical needs across various complex disease areas, including oncology, immunology, and rare genetic disorders. The company's mission involves leveraging cutting-edge scientific advancements and deep biological insights to improve patient outcomes and enhance quality of life globally.

The company's core activities begin with extensive drug discovery research, a foundational element of its operations. This involves identifying and validating new biological targets and pathways implicated in disease progression and pathology. Researchers employ advanced screening technologies, computational modeling, and sophisticated medicinal chemistry techniques to discover and optimize potential small molecule or biologic compounds. These early-stage efforts are crucial for building a robust and diverse pipeline of investigational therapies for future clinical development.

Following successful preclinical evaluation, which includes comprehensive in vitro and in vivo studies to assess safety and preliminary efficacy, Aardvark Therapeutics advances its most promising candidates into rigorous clinical development. This multi-phase process includes conducting human clinical trials to thoroughly assess the safety, tolerability, pharmacokinetics, and efficacy of its drug candidates in patient populations. The company collaborates with leading clinical investigators and healthcare institutions globally to gather comprehensive data and ensure ethical conduct. Its development programs are meticulously designed to meet stringent regulatory requirements from health authorities worldwide for potential market authorization and subsequent commercialization.

Aardvark Therapeutics primarily serves the global healthcare market, including patients, physicians, and other medical professionals who manage complex conditions. Its therapeutic products are typically distributed through a combination of direct sales forces and strategic alliances with established pharmaceutical and biotechnology partners. The company generates revenue primarily from product sales, supplemented by potential licensing agreements and milestone payments from collaborations, reaching a broad patient population worldwide.

Sector:Health Care
Country:United States
Industry:
Address:4370 La Jolla Village Drive, Suite 1050, San Diego
Employees:40
Website:aardvarktherapeutics.com

Pros

Intellectual property protection via drug patents

High switching costs for established therapies

Pricing power for novel, effective treatments

Regulatory barriers to market entry for new drugs

Potential for recurring revenue from chronic conditions

Cons

Substantial capital intensity in drug research and development

High clinical trial failure rates for drug candidates

Revenue erosion risk from patent expiry and generics

Uncertainty of regulatory approval for pipeline assets

Payer and government pressure on drug reimbursement

Company	AI Score	Compare
ARVNArvinas Inc
AKTXAkari Therapeutics PLC
APREAprea Therapeutics Inc
RCUSArcus Biosciences Inc
GRDXEntero Therapeutics Inc

	Company	AI Score	Compare
1	LBRXLB Pharmaceuticals Inc
2	PAHCPhibro Animal Health Corp
3	EYPTEyePoint Inc
4	JAZZJazz Pharmaceuticals PLC
5	GSKGSK plc
6	RAPPRapport Therapeutics Inc
7	PHVSPharvaris NV
8	LENZLENZ Therapeutics Inc
9	MAZEMaze Therapeutics Inc
10	TARSTarsus Pharmaceuticals Inc

	Company	AI Score	Compare
1	LBRXLB Pharmaceuticals Inc
2	PAHCPhibro Animal Health Corp
3	EYPTEyePoint Inc
4	JAZZJazz Pharmaceuticals PLC
5	GSKGSK plc
6	RAPPRapport Therapeutics Inc
7	PHVSPharvaris NV
8	LENZLENZ Therapeutics Inc
9	MAZEMaze Therapeutics Inc
10	TARSTarsus Pharmaceuticals Inc

Company	AI Score	Compare
ARVNArvinas Inc
AKTXAkari Therapeutics PLC
APREAprea Therapeutics Inc
RCUSArcus Biosciences Inc
GRDXEntero Therapeutics Inc

AARD Stock AI Analysis High Risk